Long‐Term Changes in Mycophenolic Acid Exposure in Combination with Tacrolimus and Corticosteroids Are Dose Dependent and Not Reflected by Trough Plasma Concentration: A Prospective Study in 100 De Novo Renal Allograft Recipients

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of clinical pharmacology

• Publication date

  2003-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0091270003256151PMID 12953344
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications

  2002cited by this paper
• Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus.

  2002cited by this paper
• Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation.

  2002cited by this paper
• Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes

  2001cited by this paper
• The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*†

  2001cited by this paper
• Comparison of the Effects of Tacrolimus and Cyclosporine on the Pharmacokinetics of Mycophenolic Acid

  2001cited by this paper
• Effect of Cyclosporine Withdrawal on Mycophenolic Acid Pharmacokinetics in Kidney Transplant Recipients With Deteriorating Renal Function: Preliminary Report

  2001cited by this paper
• DOSE OPTIMIZATION OF MYCOPHENOLATE MOFETIL WHEN ADMINISTERED WITH A LOW DOSE OF TACROLIMUS IN CADAVERIC RENAL TRANSPLANT RECIPIENTS

  2001cited by this paper
• Current Issues in Therapeutic Drug Monitoring of Mycophenolic Acid: Report of a Roundtable Discussion

  2001cited by this paper
• Canadian multicentre trial of tacrolimus/azathioprine/steroids versus tacrolimus/mycophenolate mofetil/steroids versus neoral/mycophenolate mofetil/steroids in renal transplantation.

  2001cited by this paper
• Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression

  2000cited by this paper
• Coadministration of Tacrolimus and Mycophenolate Mofetil in Stable Kidney Transplant Patients: Pharmacokinetics and Tolerability

  2000cited by this paper
• Limited sampling strategy for mycophenolic acid area under the curve.

  2000cited by this paper
• Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure.

  2000cited by this paper
• Mycophenolic Acid Area under the Curve Values in African American and Caucasian Renal Transplant Patients Are Comparable

  2000cited by this paper
• Pharmacokinetics of mycophenolic acid in renal insufficiency.

  2000cited by this paper
• The Effect of Hormones on the Expression of Five Isoforms of UDP-Glucuronosyltransferase in Primary Cultures of Rat Hepatocytes

  1999cited by this paper
• Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients.

  1999cited by this paper
• The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients

  1999cited by this paper
• Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation.

  1999cited by this paper
• Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.

  1999cited by this paper
• Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients.

  1999cited by this paper
• Comparison of MPA trough levels in patients with severe diabetes mellitus and from non-diabetics after transplantation.

  1999cited by this paper
• Stability of mycophenolic acid and mycophenolic acid glucuronide in human plasma.

  1999cited by this paper
• The Banff 97 working classification of renal allograft pathology.

  1999cited by this paper
• The Effect of Renal Insufficiency on Mycophenolic Acid Protein Binding

  1999cited by this paper
• Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study.

  1999cited by this paper
• Identification of glucoside and carboxyl‐linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil

  1999cited by this paper
• Clinical Pharmacokinetics of Mycophenolate Mofetil

  1998cited by this paper
• The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function

  1998cited by this paper
• Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation.

  1998cited by this paper
• Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.

  1998cited by this paper
• A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

  1998cited by this paper
• Pharmacokinetics of mycophenolic acid in the early period after kidney transplantation.

  1998cited by this paper
• Pharmacokinetics of Mycophenolic Acid in Renal Transplant Patients with Delayed Graft Function

  1998cited by this paper
• Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy.

  1997cited by this paper
• Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.

  1997cited by this paper
• Pharmacokinetics and Bioavailability of Mycophenolate Mofetil in Healthy Subjects after Single‐Dose Oral and Intravenous Administration

  1996cited by this paper
• Pharmacokinetics of Oral Mycophenolate Mofetil in Volunteer Subjects with Varying Degrees of Hepatic Oxidative Impairment

  1996cited by this paper
• Mycophenolate Mofetil: A Report of the Consensus Panel

  1995cited by this paper
• Gastric emptying in patients with chronic renal failure receiving hemodialysis.

  1984cited by this paper
• Some suggestions for measuring predictive performance

  1981cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Does Age Influence Immunosuppressant Drug Pharmacokinetics in Kidney Transplant Recipients?

  2024cites this paper
• Therapeutic drug monitoring of tacrolimus after kidney transplantation: trough concentration or area under curve‐based monitoring?

  2024cites this paper
• Therapeutic Drug Monitoring in Patients with Systemic Lupus Erythematosus: Utility and Gaps

  2024cites this paper
• Clinical Evidence on the Purported Pharmacokinetic Interactions between Corticosteroids and Mycophenolic Acid

  2023cites this paper
• Pharmacokinetics of free and total mycophenolic acid in paediatric and adult renal transplant recipients: Exploratory analysis of the effects of clinical factors and gene variants

  2022cites this paper
• A new lateral flow assay to detect sIL-2R during T-cell mediated rejection after kidney transplantation.

  2021cites this paper
• Effect of UGT polymorphisms on pharmacokinetics and adverse reactions of mycophenolic acid in kidney transplant patients.

  2021cites this paper
• Effects of Corticosteroid Treatment on Mycophenolic Acid Exposure in Renal Transplant Patients—Results From the SAILOR Study

  2021influential citation
• Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function

  2020cites this paper
• Pharmacokinetic evaluation of MFF in combinations with tacrolimus and cyclosporine. Findings of C0 and AUC

  2020cites this paper
• Mycophenolic Acid and Its Pharmacokinetic Drug‐Drug Interactions in Humans: Review of the Evidence and Clinical Implications

  2019cites this paper
• Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients

  2019cites this paper
• Impacto del polimorfismo MRP2 24ct en el trasplante renal en tratamiento con ácido micofenólico: farmacocinética y repercusión clínica

  2019cites this paper
• The development of a population physiologically based pharmacokinetic model for mycophenolic mofetil and mycophenolic acid in humans using data from plasma, saliva, and kidney tissue

  2019cites this paper
• Monitoring of Mycophenolic Acid Trough Concentration in Kidney Transplant under Cyclosporine Is Beneficial in Reducing Acute Rejection within 1 Year

  2018cites this paper
• Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus

  2018cites this paper
• Estimation of optimal minimum dosage of mycophenolate mofetil in children with various glomerular diseases

  2018cites this paper
• Tacrolimus and mycophenolate regimen and subclinical tubulo‐interstitial inflammation in low immunological risk renal transplants

  2017cites this paper
• mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions

  2017cites this paper
• Pharmacokinetics of mycophenolic acid in children with clinically stable idiopathic nephrotic syndrome receiving cyclosporine

  2017cites this paper
• Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience

  2017cites this paper
• Evaluation of the area under the curve of enteric-coated mycophenolate sodium using a limited sampling strategy in Chinese kidney transplant recipients
.

  2017cites this paper
• Usefulness of mycophenolic acid monitoring with PETINIA for prediction of adverse events in kidney transplant recipients

  2016cites this paper
• Comparative analysis the binding affinity of mycophenolic sodium and meprednisone with human serum albumin: Insight by NMR relaxation data and docking simulation.

  2016cites this paper
• The Value of Monitoring the Serum Concentration of Mycophenolate Mofetil in Children with Steroid-Dependent/Frequent Relapsing Nephrotic Syndrome

  2016cites this paper
• Implications of Clinical Mycophenolate Mofetil Dose According to Individual Body Weight in Japanese Renal Transplant Recipients.

  2016cites this paper
• Use of Glucuronidated Mycophenolic Acid Levels for Therapeutic Monitoring in Pediatric Lupus Nephritis Patients

  2016cites this paper
• Pharmacokinetic Variability of Mycophenolic Acid in Pediatric and Adult Patients With Hematopoietic Stem Cell Transplantation

  2016cites this paper
• Spectroscopy study and co-administration effect on the interaction of mycophenolic acid and human serum albumin.

  2015cites this paper
• Pharmacokinetics of mycophenolate mofetil in Omani patients on cyclosporine or tacrolimus.

  2015cites this paper
• Untersuchungen zur Pharmakokinetik und Pharmakodynamik von Mycophenolatmofetil im ersten Jahr nach Nierentransplantation

  2015cites this paper
• Limited Sampling Strategy for Mycophenolic Acid in Chinese Kidney Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus During the Early Posttransplantation Phase

  2015cites this paper
• Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention

  2014cites this paper
• A Population Pharmacokinetic Analysis for Enteric-coated Mycophenolate Sodium Using Non-linear Mixed Effect Model in Korean Kidney Transplant Recipients

  2014cites this paper
• Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?

  2014cites this paper
• Development and Validation of Limited Sampling Strategies for the Estimation of Mycophenolic Acid Area Under the Curve in Adult Kidney and Liver Transplant Recipients Receiving Concomitant Enteric-Coated Mycophenolate Sodium and Tacrolimus

  2013cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Patients with Autoimmune Disease

  2013cites this paper
• Limited sampling strategy for the estimation of mycophenolic acid area under the concentration-time curve treated in Japanese living-related renal transplant recipients with concomitant extended-release tacrolimus.

  2013cites this paper
• Mycophenolic Acid Absorption Profiles in Patients with Kidney or Combined Pancreas-Kidney Transplantation

  2012cites this paper
• Identification of the Genotype – Phenotype Correlation in the Inosine Monophosphate Dehydrogenase Enzyme

  2012cites this paper
• Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week

  2012cites this paper
• Mycophenolic Acid Pharmacokinetics During Maintenance Immunosuppression in African American and Caucasian Renal Transplant Recipients

  2011cites this paper
• Maximum A Posteriori Bayesian Estimation of Mycophenolic Acid Area Under the Concentration-Time Curve: Is This Clinically Useful for Dosage Prediction Yet?

  2011cites this paper
• Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus.

  2011cites this paper
• Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.

  2011cites this paper
• A Possible Simplification for the Estimation of Area Under the Curve (AUC0–12) of Enteric-Coated Mycophenolate Sodium in Renal Transplant Patients Receiving Tacrolimus

  2011cites this paper
• Mycophenolic acid agents: is enteric coating the answer?

  2011cites this paper
• die Bioverfügbarkeit von Mycophenolsäure aus CellCept® bzw. myfortic®: Pharmakokinetische Untersuchungen in vitro und an Probanden.

  2011cites this paper
• Development and Validation of Limited Sampling Strategies for Tacrolimus and Mycophenolate in Steroid-Free Renal Transplant Regimens

  2011cites this paper
• Renal Graft Function and Low-Dose Cyclosporine Affect Mycophenolic Acid Pharmacokinetics in Kidney Transplantation

  2011cites this paper
• Pharmacokinetics of mycophenolic acid in living donor liver transplantation.

  2010cites this paper
• Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements.

  2010cites this paper
• Pharmacogenetic Impact of UDP‐Glucuronosyltransferase Metabolic Pathway and Multidrug Resistance—Associated Protein 2 Transport Pathway on Mycophenolic Acid in Thoracic Transplant Recipients: An Exploratory Study

  2010cites this paper
• Mycophenolic acid trough level measurements and clinical outcomes in kidney transplantation recipients on a fixed dose (1.5 g/d) of mycophenolate mofetil in Korea.

  2010cites this paper
• Mycophenolic Acid Exposure in High- and Low-Weight Renal Transplant Patients After Dosing With Mycophenolate Mofetil in the Opticept Trial

  2010cites this paper
• Population Pharmacokinetic Analysis of Mycophenolic Acid Coadministered With Either Tasocitinib (CP-690,550) or Tacrolimus in Adult Renal Allograft Recipients

  2010cites this paper
• Evaluation of the Mycophenolic Acid Exposure Estimation Methods Used in the APOMYGERE, FDCC, and Opticept Trials

  2010cites this paper
• Pharmacodynamic Monitoring of Inosine Monophosphate Dehydrogenase Activity: A Basis For Optimized and Individualized Mycophenolate Mofetil Therapy

  2010influential citation
• Pharmacogenetic influences on mycophenolate therapy.

  2010cites this paper
• Immunosuppression armamentarium in 2010: mechanistic and clinical considerations.

  2010cites this paper
• Variability in the pharmacokinetics of mycophenolic acid: Implications for therapeutic drug monitoring

  2010influential citation
• Pharmacokinetics of mycophenolic acid in severe lupus nephritis.

  2010cites this paper
• New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation

  2009cites this paper
• Pharmacokinetics and limited sampling strategies of mycophenolic acid in islet transplant recipients

  2009influential citation
• Limited Sampling Strategies Drawn Within 3 Hours Postdose Poorly Predict Mycophenolic Acid Area-Under-the-Curve After Enteric-Coated Mycophenolate Sodium

  2009cites this paper
• Therapeutic monitoring of mycophenolate in transplantation: is it justified?

  2009cites this paper
• Increased Mycophenolic Acid Exposure in Stable Kidney Transplant Recipients on Tacrolimus as Compared With Those on Sirolimus: Implications for Pharmacokinetics

  2009cites this paper
• Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients.

  2009cites this paper
• Longitudinal evaluation of mycophenolic acid pharmacokinetics in pediatric kidney transplant recipients. The role of post‐transplant clinical and therapeutic variables

  2009cites this paper
• Performance of the New Mycophenolate Assay Based on IMPDH Enzymatic Activity for Pharmacokinetic Investigations and Setup of Bayesian Estimators in Different Populations of Allograft Recipients

  2009cites this paper
• EC‐MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF‐related gastrointestinal side‐effects

  2009cites this paper
• A limited sampling strategy for estimating mycophenolic acid area under the curve in adult heart transplant patients treated with concomitant cyclosporine

  2009cites this paper
• Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard‐dose or reduced‐dose tacrolimus in liver transplant recipients

  2009cites this paper
• Pharmacokinetics of Mycophenolic Acid and Its Glucuronide Metabolites in Stable Adult Liver Transplant Recipients With Renal Dysfunction on a Low-Dose Calcineurin Inhibitor Regimen and Mycophenolate Mofetil

  2009cites this paper
• Does the Evidence Support the Use of Mycophenolate Mofetil Therapeutic Drug Monitoring in Clinical Practice? A Systematic Review

  2008influential citation
• Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring.

  2008cites this paper
• Utility of monitoring mycophenolic acid in solid organ transplant patients.

  2008influential citation
• Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.

  2008cites this paper
• Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients

  2008cites this paper
• Stability of mycophenolic acid and glucuronide metabolites in human plasma and the impact of deproteinization methodology.

  2008cites this paper
• Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation

  2008cites this paper
• Higher Mycophenolate Dose Requirements in Children Undergoing Hematopoietic Cell Transplant (HCT)

  2008cites this paper
• Corticosteroid Interactions with Cyclosporine, Tacrolimus, Mycophenolate, and Sirolimus: Fact or Fiction?

  2008cites this paper
• Development of a Predictive Limited Sampling Strategy for Estimation of Mycophenolic Acid Area Under the Concentration Time Curve in Patients Receiving Concomitant Sirolimus or Cyclosporine

  2008cites this paper
• Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors

  2008cites this paper
• Therapeutic drug monitoring of mycophenolic acid.

  2007cites this paper
• Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?

  2007cites this paper
• Time-dependent clearance of mycophenolic acid in renal transplant recipients.

  2007cites this paper
• Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients.

  2007cites this paper
• Why and How to Perform Therapeutic Drug Monitoring for Mycophenolate Mofetil

  2007cites this paper
• Avaliação da biodisponibilidade de uma nova formulação de micofenolato mofetil e de um método para sua monitorização terapêutica

  2007cites this paper
• Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil

  2007cites this paper
• Individualisation of mycophenolate mofetil therapy

  2007cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients

  2007cites this paper
• C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.

  2007cites this paper
• Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients

  2007cites this paper
• Pharmacokinetics of Mycophenolic Acid and Estimation of Exposure Using Multiple Linear Regression Equations in Chinese Renal Allograft Recipients

  2007cites this paper
• Individualization of mycophenolate mofetil dose in renal transplant recipients.

  2006cites this paper
• Pharmacokinetics of Mycophenolic Acid and Its Glucuronidated Metabolites in Stable Lung Transplant Recipients

  2006cites this paper
• A Limited Sampling Model for Estimation of Total and Unbound Mycophenolic Acid (MPA) Area Under the Curve (AUC) in Hematopoietic Cell Transplantation (HCT)

  2006cites this paper